Overview

• Temperature-controlled supply chain firm's FY 2025 revenue rose 12% yr/yr, exceeding guidance

• Life sciences services revenue grew 18% yr/yr, BioStorage/BioServices up 22%

• Company formed strategic partnership with DHL, enhancing EMEA and APAC presence

Outlook

• Cryoport provides full-year 2026 revenue guidance of $190 mln to $194 mln

• Company anticipates 13 BLA/MAA filings and nine new therapy approvals in 2026

Result Drivers

• CELL AND GENE THERAPY REVENUE - Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 mln for FY 2025

• CLINICAL TRIAL SUPPORT - Supported a record 760 global clinical trials, representing approximately 70% of CGT trials, at year end

Company press release: ID:nPn2kglRSa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the courier, postal, air freight & land-based logistics peer group is "buy"

• Wall Street's median 12-month price target for Cryoport Inc is $13.00, about 58.3% above its March 2 closing price of $8.21

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)